DAIICHI SANKYO, INC.

DAIICHI SANKYO, INC. logo
🇺🇸United States
Ownership
Subsidiary
Established
2010-01-01
Employees
10K
Market Cap
$79B
Website
http://daiichisankyo.us
Clinical Trials
Related News

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.

First Posted Date
2005-09-09
Last Posted Date
2012-01-18
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
796
Registration Number
NCT00151788

Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes

First Posted Date
2005-09-07
Last Posted Date
2014-04-02
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
36
Registration Number
NCT00147745
Locations
🇺🇸

San Diego VMC, San Diego, California, United States

WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Type 2 Diabetes
First Posted Date
2005-09-07
Last Posted Date
2012-01-18
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
400
Registration Number
NCT00147758

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Type 2 Diabetes
First Posted Date
2005-09-07
Last Posted Date
2012-01-18
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
300
Registration Number
NCT00147719
Locations
🇺🇸

CRO, Jonesboro, Arkansas, United States

Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol

Phase 4
Completed
Conditions
Hypercholesterolemia
Interventions
Drug: colesevelam HCl
Drug: placebo
First Posted Date
2005-09-05
Last Posted Date
2010-04-15
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
194
Registration Number
NCT00145574

Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes

Phase 2
Completed
Conditions
Type 2 Diabetes
First Posted Date
2005-09-02
Last Posted Date
2021-05-10
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
441
Registration Number
NCT00143520

Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement

Phase 2
Completed
Conditions
Thrombosis
Arthroplasty, Replacement, Hip
Interventions
Drug: DU-176b
First Posted Date
2005-04-12
Last Posted Date
2019-02-26
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
606
Registration Number
NCT00107900
Locations
🇺🇸

Local Institution, Decatur, Georgia, United States

DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas

Phase 2
Completed
Conditions
Pancreatic Cancer
First Posted Date
2004-08-18
Last Posted Date
2012-05-16
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
37
Registration Number
NCT00003951
Locations
🇺🇸

Johns Hopkins Oncology Center, Baltimore, Maryland, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer

First Posted Date
2004-07-19
Last Posted Date
2012-05-16
Lead Sponsor
Daiichi Sankyo
Registration Number
NCT00004060
Locations
🇺🇸

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy in Treating Patients Who Have Hematologic Cancer

Phase 1
Completed
Conditions
Myelodysplastic Syndromes
Leukemia
First Posted Date
2004-07-19
Last Posted Date
2012-05-16
Lead Sponsor
Daiichi Sankyo
Registration Number
NCT00004047
Locations
🇺🇸

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy